Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
Other · Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Conditions
Squamous Cell Carcinomas
Interventions
Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
New York, New York
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions
paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Interventions
docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
MRI
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer
Interventions
Intensity modulated radiotherapy (IMRT), PET-MRI
Radiation · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Cetuximab, Cisplatin, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
Interventions
RPTR-168
Biological
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Ann Arbor, Michigan + 1 more
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
HPV16+ Squamous Cell Carcinoma
Interventions
HB-200
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cyclophosphamide, IRX-2, Nivolumab, Surgery
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Recruiting Phase 2 Interventional Accepts healthy volunteers

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

NCT07172256
Conditions
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
Interventions
CUE-101, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay, FDA-Approved HPV DNA Test
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
12,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Conditions
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
Interventions
HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
Genetic · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Assessment of Oral HPV Infection
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
Interventions
NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray
Diagnostic Test · Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Conditions
Cervical Cancer
Interventions
Proflavine, HRME Imaging, Phone Call, Colposcopy, Acetic Acid
Drug · Device · Behavioral + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Houston, Texas
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions
Pembrolizumab (KEYTRUDA®) and PDS0101
Combination Product
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more